Multiple Myeloma Patient Registry

Janssen Scientific Affairs, LLC85 enrolled

Overview

The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Multiple Myeloma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must sign, and/or their legally acceptable representative where applicable must sign, a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements * Have a diagnosis of relapsed MM \[according to 2014 International Myeloma Working Group (IMWG) criteria\] with 1 to 3 prior lines of therapy. (An induction regimen followed by autologous stem cell transplantation and single-agent maintenance therapy will be considered a single line of therapy.) * Participants must have initiated a new line of induction therapy that includes a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 90 days prior to enrollment. A short course of corticosteroids is allowed prior to initiating the new line of induction therapy * Must be willing and able to complete the protocol-required patient-reported outcome (PROs) Exclusion Criteria: * Participant has plasma cell leukemia \[greater than (\>) 2.0 \* 10\^9 per liter\] circulating plasma cells by standard differential), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and/or skin changes), or amyloid light-chain amyloidosis * Participant has a life expectancy of less than 6 months * At the time of screening, participant is enrolled in an interventional clinical trial for MM using an anti-neoplastic agent that is not currently approved by the United States (US) Food and Drug Administration (FDA)

Locations (69)

Outcomes

Primary Outcomes

Overall Response Rate

Overall response rate defined as the percentage of participants achieving Complete Response (CR), Very good partial response (VGPR), or Partial response (PR) (CR + VGPR + PR) as per International Myeloma Working Group (IMWG 2016) criteria. CR as negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and less than(\<) 5 percent (%) plasma cells in bone marrow(BM). VGPR as serum and urine M-protein (monoclonal paraprotein) detectable by immunofixation but not on electrophoresis or 90% or greater than (\>) reduction in serum and urine M-protein level \<100 milligram (mg) per 24 hour (hr). PR as greater than or equal to (\>=) 50% reduction of serum M-protein and less than (\>=) 90% of urine M-protein or up to \<200 mg per 24 hour.

Time frame: Up to 3 years

Time to Next Treatment (TTNT)

TTNT is defined as the time from the date of initiation of regimen for induction to the initiation of next regimen for each successive therapy received.

Time frame: Up to 3 years

Overall Survival (OS)

OS is defined as the time from the date of initiation of therapy to the date of death from any cause (or last documented follow-up).

Time frame: Up to 3 years

Survival Time

Survival time is defined as the time from the start of each respective treatment to death (or last documented follow-up).

Time frame: Up to 3 years

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score

EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer participants. It is composed of 30 items, multiitem measure (28 items) and 2 single-item measures. For the multiple item measure, 4 point scale is used and the score for each item range from "1 = not at all" to "4 = very much". Higher scores indicate worsening. The 2 single-item measure involves question about the overall health and overall quality of life which will be rated on a 7 point scale ranging from "1 = very poor" to "7 = excellent". Lower scores indicate worsening. Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Arizona Oncology Associates, PC - HAL

Phoenix, Arizona, United States

Mercy Research

Fort Smith, Arkansas, United States

Genesis Cancer Center

Hot Springs, Arkansas, United States

St. Bernard's Medical Center

Jonesboro, Arkansas, United States

CARTI

Little Rock, Arkansas, United States

Facey Medical Group

Mission Hills, California, United States

North County Oncology

Oceanside, California, United States

Ventura County Hematology Oncology Specialists

Oxnard, California, United States

James R. Berenson, MD Inc.

West Hollywood, California, United States

PIH Health Hospital

Whittier, California, United States

...and 59 more locations